SkinVision
Develops a regulated smartphone application for early detection and monitoring of skin cancer.
What they do
SkinVision provides a regulated mobile application that enables individuals to assess their skin for signs of cancer. Consumers and insurers use the camera-based, AI-powered tool to analyze moles and lesions, receiving risk assessments and recommendations for dermatological follow-up care.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening
- Product type
- Software as a medical device
- Stage
- Series B
- Headquarters
- Amsterdam, Netherlands
- Region
- Europe
- Founded
- 2011
- Total funding
- $10M raised
Notable investors: Leo Pharma, PHS Fund.